Author

Janice Drew

Observed names: Drew, J., J Drew, J. Drew, Janice S. Drew

Observed institution: Dermira (United States)

OpenAlex ID: A5081878322

Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis

2020 · Emma Guttman-Yassky, Andrew Blauvelt, et al. · JAMA Dermatology · 351

PDF

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)

2018 · Alice B. Gottlieb, Andrew Blauvelt, et al. · Journal of the American Academy of Dermatology · 157

PDF

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)

2018 · Mark Lebwohl, Andrew Blauvelt, et al. · Journal of the American Academy of Dermatology · 133

Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials

2018 · Dee Anna Glaser, Adelaide A. Hebert, et al. · Journal of the American Academy of Dermatology · 82

Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials

2018 · David M. Pariser, Adelaide A. Hebert, et al. · American Journal of Clinical Dermatology · 43

PDF

Certolizumab pegol for the treatment of patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials

2018 · A. Blauvelt, K. Reich, et al. · Journal of the European Academy of Dermatology and Venereology · 38

PDF

Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study

2016 · Robert Bissonnette, Yves Poulin, et al. · Journal of the American Academy of Dermatology · 38

A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis

2019 · Dee Anna Glaser, Adelaide A. Hebert, et al. · American Journal of Clinical Dermatology · 35

PDF

Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials

2018 · Adelaide A. Hebert, Dee Anna Glaser, et al. · Pediatric Dermatology · 34

PDF

Long‐term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44‐week open‐label extension study

2020 · Adelaide A. Hebert, Dee Anna Glaser, et al. · Pediatric Dermatology · 23

PDF

Limited Systemic Exposure with Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis

2021 · David M. Pariser, Edward L. Lain, et al. · Clinical Pharmacokinetics · 18

PDF

Development and validation of the Axillary Sweating Daily Diary: a patient-reported outcome measure to assess axillary sweating severity

2019 · L. M. Nelson, D. DiBenedetti, et al. · Journal of Patient-Reported Outcomes · 17

PDF

Lebrikizumab, a High-Affinity IL-13 Inhibitor, Improves Clinical Manifestations in Moderate-to-Severe Atopic Dermatitis: Primary Results From a Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Phase 2b Study

2019 · E Guttman-Yassky, A Blauvelt, et al. · SKIN The Journal of Cutaneous Medicine · 4

Confirmatory Psychometric Evaluation of the Axillary Sweating Daily Diary: A Vaildated Patient-Reported Outcome Measure to Assess Axillary Hyperhidrosis Sweating Severity

2017 · Dee Anna Glaser, Adelaide A Hebert, et al. · SKIN The Journal of Cutaneous Medicine · 4

PDF

Maintenance of Response with Certolizumab Pegol for the Treaatment of Chronic Plaque Psoriasis: Results of a 32-Week Re-Randomized Maintenance Period from an Onging Phase 3, Multicenter, Randomized, Active- and Placebo-Controlled Study (CIMPACT)

2017 · Matthias Augustin, Jolanta Weglowska, et al. · SKIN The Journal of Cutaneous Medicine · 2

PDF

Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: DLQI and WPAI Patient-Reported Outcomes from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2)

2017 · Diamant Thaci, Alice Gottlieb, et al. · SKIN The Journal of Cutaneous Medicine · 2

PDF

Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: DLQI and WPAI Patient-Reported Outcomes from an Ongoing Phase 3, Multicenter, Randomized, Active- and Placebo-Controlled Study (CIMPACT)

2017 · Vincent Piguet, Andrew Blauvelt, et al. · SKIN The Journal of Cutaneous Medicine · 2

PDF

Open-Label Study (ARIDO) Evaluating Long-Term Safety of Topical Glycopyrronium Tosylate (GT) in Patients with Axillary Hyperhidrosis

2017 · Dee Anna Glaser, Adelaide A Hebert, et al. · SKIN The Journal of Cutaneous Medicine · 2

PDF

1020 EVO756: An emerging oral MRGPRX2 inhibitor with compelling data from early studies

2025 · J. Harden, S. Bagchi, et al. · Journal of Investigative Dermatology · 1

PDF

Short- and Long-Term Efficacy and Safety of Glycopyrronium Cloth for the Treatment of Primary Axillary Hyperhidrosis: Post Hoc Pediatric Subgroup Analyses from the Phase 3 Studies

2018 · Adelaide A Hebert, Dee Anna Glaser, et al. · SKIN The Journal of Cutaneous Medicine · 1

PDF

Open-Label Study (ARIDO) Evaluating Long-Term Safety of Topical Glycopyrronium Tosylate (GT) in Patients with Primary Axillary Hyperhydrosis

2018 · Dee Anna Glaser, Adelaide A Hebert, et al. · SKIN The Journal of Cutaneous Medicine · 1

PDF

16428 Lebrikizumab, a high-affinity interleukin-13 inhibitor, improves clinical manifestations in moderate to severe atopic dermatitis: Time course of response from a randomized, double-blinded, placebo-controlled, dose-ranging, phase 2b study

2020 · Emma Guttman-Yassky, Andrew Blauvelt, et al. · Journal of the American Academy of Dermatology

Impact of Lebrikizumab on Patient-Reported Outcomes in Atopic Dermatitis: Prospective and Post Hoc Analyses of a Phase 2b Clinical Trial Demonstrate Clinically Meaningful Improvements

2020 · E Guttman-Yassky, A Blauvelt, et al. · SKIN The Journal of Cutaneous Medicine

PDF

Limited Systemic Exposure with Topical Glycopyrronium Tosylate across Multiple Studies in Healthy Volunteers and Patients with Primary Axillary Hyperhidrosis

2019 · D.M. Pariser, E.L. Lain, et al. · SKIN The Journal of Cutaneous Medicine

PDF

Onset of Action With Glycopyrronium Cloth in the Treatment of Primary Axillary Hyperhidrosis

2018 · D Pariser, L Green, et al. · SKIN The Journal of Cutaneous Medicine

PDF

Works count: 32

Citation count: 988

H-index: 12

I10-index: 12